Compare CNK & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | FOLD |
|---|---|---|
| Founded | 1984 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2007 | 2007 |
| Metric | CNK | FOLD |
|---|---|---|
| Price | $24.59 | $10.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $35.30 | $30.29 |
| AVG Volume (30 Days) | ★ 4.4M | 4.2M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $3,153,000,000.00 | $598,704,000.00 |
| Revenue This Year | $6.71 | $21.49 |
| Revenue Next Year | $7.78 | $18.25 |
| P/E Ratio | $22.08 | ★ N/A |
| Revenue Growth | 9.70 | ★ 21.28 |
| 52 Week Low | $21.62 | $5.51 |
| 52 Week High | $34.01 | $10.79 |
| Indicator | CNK | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 75.23 |
| Support Level | $21.62 | $9.73 |
| Resistance Level | $25.57 | $10.05 |
| Average True Range (ATR) | 1.32 | 0.37 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 36.18 | 99.54 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.